Literature DB >> 22336853

Timing of hypertonic saline inhalation for cystic fibrosis.

Mark Elkins1, Ruth Dentice.   

Abstract

BACKGROUND: Inhalation of hypertonic saline improves sputum rheology, accelerates mucociliary clearance and improves clinical outcomes of people with cystic fibrosis.
OBJECTIVES: To determine whether the timing of hypertonic saline inhalation (in relation to airway clearance techniques or in relation to time of day) has an impact on its clinical efficacy in people with cystic fibrosis. SEARCH
METHODS: We identified relevant randomised and quasi-randomised controlled trials from the Cochrane Cystic Fibrosis Trials Register, the Physiotherapy Evidence Database (PEDro), and international cystic fibrosis conference proceedings.Date of the last search of the Group's Cystic Fibrosis Trials Register: 6 December 2011. SELECTION CRITERIA: Any trial of hypertonic saline in people with cystic fibrosis where timing of inhalation was the randomised element in the study protocol with either: inhalation up to six hours before airway clearance techniques compared to inhalation during airway clearance techniques compared to inhalation up to six hours after airway clearance techniques; or morning compared to evening inhalation with any definition provided by the author. DATA COLLECTION AND ANALYSIS: Both authors independently assessed the trials identified by the search for potential inclusion in the review. MAIN
RESULTS: The search strategy identified 50 trial reports which represented 24 unique studies. One study, published only as an abstract, is awaiting further assessment. None of the other studies compared timing regimens for the inhalation of hypertonic saline and we excluded these from the review. AUTHORS'
CONCLUSIONS: This review did not identify any evidence comparing the timing of hypertonic saline inhalation in relation to airway clearance physiotherapy. Until such evidence becomes available, clinicians could advise patients to inhale hypertonic saline before airway clearance, because this is the only regimen evaluated in the studies that established the efficacy of the use of hypertonic saline. This review also did not identify any evidence comparing the timing of hypertonic saline inhalation in relation to time of day. Until such evidence becomes available, clinicians could advise patients to inhale hypertonic saline morning and evening; but if only one dose per day is tolerated, the time of day at which it is inhaled could be based on convenience or tolerability.Given the competing theoretical rationales about why hypertonic saline could be more effective if inhaled at certain times, a trial comparing these various timing regimens should be conducted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22336853     DOI: 10.1002/14651858.CD008816.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  6 in total

Review 1.  Timing of hypertonic saline inhalation for cystic fibrosis.

Authors:  Mark Elkins; Ruth Dentice
Journal:  Cochrane Database Syst Rev       Date:  2016-12-22

Review 2.  Structure and function of the mucus clearance system of the lung.

Authors:  Brenda M Button; Brian Button
Journal:  Cold Spring Harb Perspect Med       Date:  2013-08-01       Impact factor: 6.915

3.  Timing of hypertonic saline inhalation for cystic fibrosis.

Authors:  Mark Elkins; Ruth Dentice
Journal:  Cochrane Database Syst Rev       Date:  2020-02-28

4.  Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study.

Authors:  Katherine O'Neill; Fidelma Moran; Michael M Tunney; J Stuart Elborn; Ian Bradbury; Damian G Downey; Jackie Rendall; Judy M Bradley
Journal:  BMJ Open Respir Res       Date:  2017-01-12

Review 5.  Inhaled therapy in cystic fibrosis: agents, devices and regimens.

Authors:  Penny Agent; Helen Parrott
Journal:  Breathe (Sheff)       Date:  2015-06

6.  New insights into the mechanisms controlling the bronchial mucus balance.

Authors:  Cyril Karamaoun; Benjamin Sobac; Benjamin Mauroy; Alain Van Muylem; Benoît Haut
Journal:  PLoS One       Date:  2018-06-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.